Glenmark passes the benefits to patients by reducing the price of oral antiviral FabiFlu by 27 in India
| Thursday | 16th July, 2020
Further, Glenmark has announced a price reduction of27% for FabiFlu®.
FabiFlu® in India was originally launched at INR 103/tab, while, its price as INR is higher in the remaining countries.
(INR 600/tab in Russia, INR 378/tab in Japan, INR 350/tab in Bangladesh and INR 215/tab in China).
Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu®) in mild to moderate COVID-19 patients in India.
The combination study which is called the FAITH trial is looking to enroll 158 hospitalized patients of moderate COVID-19 in India.